AdvanDx is a molecular diagnostic company committed to provide the medical profession with advanced in vitro diagnostic kits, such as PNA FISH for rapid and simple pathogen identification in blood cultures and screening test for the prevention of hospital acquired infections, leading to improved therapy and better patient management.Visit site
Gyros AB is a Swedish-based company located in Uppsala. The company’s automated platform, Gyrolab®, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins.
Gyrolab enables assays to be conducted with a significantly reduced background, increased dynamic range and with higher throughput. All this is achieved using only nanoliter volumes of reagents and sample. More data can be generated in less time and with higher precision, consequently improving productivity and effectiveness. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.
Many major pharmaceutical companies and service providers— CMOs/CROs—have already implemented multiple Gyrolab platforms to boost their drug development process and to meet increasing regulatory demands on testing.
Light Sciences Oncology, Inc.
Light Sciences Oncology, Inc. (LSO) was incorporated in late 2004 to develop and commercialize the technology of Light Sciences Corporation in the medical field.Visit site
Medical Vision AB
Medical Vision AB was founded in 2002 and focuses on endoscopy. The Company develops and produces a broad range of products used during endoscopic procedures including the Double®Pump which provides automated pressure and flow control thereby facilitating surgeon procedures in arthroscopy.Visit site
Nuevolution A/S is a drug discovery company based on its proprietary Chemetics™ technologies to rapidly identify multiple drug candidates to virtually any target in very short time.Visit site
An Asset Purchase Agreement (APA) has been signed and executed with Medtronic Inc.Visit site